SUMMIT: Bezuclastinib Delivers Durable, Deepening Symptom Relief in NonAdvSM, With Cem Akin, MD

Bezuclastinib, an oral, highly selective type 1 KIT inhibitor, has demonstrated that clinically meaningful symptom improvement not only holds but continues to deepen out to 48 weeks of treatment in patients with nonadvanced systemic mastocytosis (NonAdvSM), with every assessed symptom domain showing progressive gains over the treatment course.

These data were from the pivotal, multicenter, randomized, double-blind, placebo-controlled phase 2 SUMMIT trial and were presented at the 

American Academy of Allergy, Asthma & Immunology (AAAAI)

 2026 Annual Meeting held in Philadelphia, Pennsylvania.

The trial is evaluating bezuclastinib 100 mg once daily versus placebo in patients with NonAdvSM (n = 179; bezuclastinib, n = 119; placebo, n = 60). To discuss the findings and what they mean for a patient population with limited established options, 

 spoke with Cem Akin, MD, Professor of Medicine at the University of Michigan Division of Allergy and Immunology, a leading authority in mast cell disorders and a principal investigator on the trial, during the meeting. Akin also discussed the importance of prioritizing the symptom burden in patients with NonAdvSM, as visualized with SUMMIT trial entry interviews, which were highlighted in the poster he presented at the meeting.

Across the MS2D2 Total Symptom Score, bezuclastinib produced broad, sustained reductions from a mean baseline score of 8.1. At 48 weeks, mean changes from baseline were observed across all symptom domains: itching (–5.2), flushing (–5.1), skin papules (–5.2), fatigue (–6.0), cognitive concentration (–7.3), memory (–5.7), nausea (–5.5), abdominal pain (–3.3), headache (–4.3), bone pain (–4.0), diarrhea (–5.6), brain fog (–3.0), and dizziness (–3.4) — with all symptoms showing deepening improvement from the 24-week timepoint. In total, 86% of bezuclastinib-treated patients achieved a ≥30% reduction in MS2D2 TSS (81/94), and 56.4% achieved ≥50% reduction (53/94) at 48 weeks.

“These interviews were conducted before they were enrolled in the trial, and they focused on different domains, like skin, gastrointestinal, neurocognitive domains and there are some sentences taken directly from the patient interview that kind of tells you the impact of these patients are experiencing. And some of them are really very severe. And I think for somebody who is new to the field, it is absolutely eye opening to recognize what the patient's going through,” Akin said.

On biomarker endpoints, 98.9% of patients (88/89) in the bezuclastinib arm achieved ≥50% reduction in serum tryptase at week 48, compared to 96.1% (49/51) among placebo crossover patients — with median serum tryptase of 4.7 ng/mL (range 1.0–128.0) versus 5.8 ng/mL (range 1.1–143.0), respectively. Patients achieving tryptase below 20 ng/mL reached 91.7% (66/72), and 83.3% (70/84) fell below 11.4 ng/mL. KIT p.D816V variant allele fraction in peripheral blood was reduced to a median of 0.04% (range, 0–10.5) in the bezuclastinib arm versus 0.07% (range 0–12.1) in placebo crossovers, with 98.4% (61/62) of the ITT population achieving ≥50% VAF reduction. The tolerability profile remained favorable through 48 weeks, with serious TEAEs occurring in just 1.7% of bezuclastinib-treated patients and discontinuations due to TEAEs in 9.2% (11/119 in the double-blind period).

Cogent Biosciences submitted a new drug application (NDA) for a broad NonAdvSM indication in December 2025.

Akin’s disclosures include Blueprint Medicines, Cogent, Telios, GSK, and Novartis.

Boggs NA, Rein L, Bose P, et al. Expanded Results From the Phase 2 Summit Trial: Bezuclastinib in Adults With Nonadvanced Systemic Mastocytosis. Presented at: AAAAI 2026 Annual Meeting, February 27-March 2, Philadelphia, Pennsylvania. Abstract #519

Akin C, Boggs NA, Rein L, et al. Results From the Phase 2 Summit Trial of Bezuclastinib in Adults With Nonadvanced Systemic Mastocytosis (NonAdvSM): Patient Experience of Living With NonAdvSM. Presented at: AAAAI 2026 Annual Meeting, February 27-March 2, Philadelphia, Pennsylvania. Abstract #510

Cogent Biosciences announces submission of new drug application for bezuclastinib in nonadvanced systemic mastocytosis. News release. Cogent Biosciences, Inc. December 30, 2025. Accessed January 2, 2025. https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-submission-new-drug-application

Videos

Cogent Biosciences previously submitted an NDA for bezuclastinib at the end of 2025.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Girish Nadkarni, MD, MPH, is the Irene and Dr. Arthur M. Fishberg Professor of Medicine, System Chief of the Division of Data Driven and Digital Medicine , Co-Director of the Mount Sinai Clinical Intelligence Center, and the Director of Charles Bronfman Institute for Personalized Medicine.

The Hidden Dangers of AI-Generated Medical Advice, With Girish Nadkarni, MD, MPH

As large language models (LLMs) become increasingly embedded in everyday life, more patients are turning to consumer-facing AI tools for health information and advice, raising critical questions about what happens when misinformation enters these systems.

That concern is at the heart of a new study from researchers at the Icahn School of Medicine at Mount Sinai, who conducted a large-scale evaluation of how LLMs handle medical misinformation. In an interview with HCPLive, Girish Nadkarni, MD, MPH, the Irene and Dr. Arthur M. Fishberg Professor of Medicine, System Chief of the Division of Data Driven and Digital Medicine , Co-Director of the Mount Sinai Clinical Intelligence Center and the Director of Charles Bronfman Institute for Personalized Medicine, emphasized that today’s AI models are trained broadly on internet data rather than exclusively on vetted medical sources, raising important concerns about patient safety.

To stress test these systems, he and a team of investigators exposed multiple widely used LLMs, including ChatGPT and Gemini, as well as health-specific AI models, to 3 types of content: authentic hospital discharge summaries altered to include a single piece of misinformation, common health myths drawn from social media platforms such as Reddit, and 300 short clinical vignettes embedded with misleading claims. Each scenario was presented in both neutral and emotionally charged language to mirror how misinformation often appears online.

Across platforms, the researchers observed that LLMs frequently passed along misinformation rather than correcting it, with LLMs found to be susceptible to fabricated data in 50,108 (31.7%) of 158,000 base prompts. Of note, 8 of 10 fallacy framings significantly reduced or did not change that rate, led by appeal to popularity (susceptibility 11.9%; difference of –19.8 percentage points; 

<.0001). Real hospital notes with fabricated inserted elements produced the highest susceptibility to the base prompt (46.1%), whereas social media misinformation showed lower base prompt susceptibility (8.9%).

Results showed performance varied by model: GPT models were the least susceptible and most accurate at fallacy detection, whereas others, such as Gemma-3–4B-it, showed 63.6% susceptibility.

“We had a discharge note which advised patients with bleeding in the GI tract to drink cold milk to suit the symptoms. It sounds reasonably easy enough to do, but if you just drink cold milk to soothe the symptoms and you actually have bleeding in a GI tract, as opposed to going to the emergency room, that can actually be really dangerous and really fatal,” Nadkarni said. “Several models accepted the statement rather than flagging it as unsafe, and they treated it like ordinary medical guidance.”

According to Nadkarni, these findings are particularly concerning because these AI systems are highly fluent and persuasive. Patients may bring AI-generated recommendations to clinicians as if they are established fact, adding to clinical burden and potentially introducing risk.

“Large language models are extremely good at sounding convincing and presenting information to patients that they want to hear,” he said. “Anything that's generated by large language models, I think there should be some amount of human oversight, particularly clinician oversight, on top of this.”

The findings underscore the need for stronger evaluation frameworks for medical AI. Nadkarni argues that assessment must extend beyond single-use testing to include ongoing monitoring. Because LLMs are continuously retrained and updated, performance can shift over time. Identifying failure modes, implementing engineering safeguards or human oversight, and regularly reassessing models are critical steps toward safer deployment.

While no technology can be made entirely risk-free, the goal, Nadkarni noted, is risk mitigation. For clinicians and patients alike, he says this means approaching AI-generated medical information with caution, prioritizing trusted sources, and recognizing that convincing language does not guarantee clinical accuracy.

Editors’ note: Nadkarni reports no relevant disclosures.

Mount Sinai. Can Medical AI Lie? Large Study Maps How LLMs Handle Health Misinformation. February 9, 2026. Accessed March 3, 2026. 

https://www.mountsinai.org/about/newsroom/2026/can-medical-ai-lie-large-study-maps-how-llms-handle-health-misinformation

Omar M, Sorin V, Wieler LH, et al. Mapping the susceptibility of large language models to medical misinformation across clinical notes and social media: a cross-sectional benchmarking analysis. Lancet. doi:

Nadkarni’s research suggests LLMs often pass along medical misinformation, underscoring the need for oversight, evaluation, and stronger AI guardrails.

Internal Medicine

Internal Medicine condition center page, resources on the topics of medical news and expert insight into internal medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on internal medicine research, treatment, and drug development.

Mapping Medical Misinformation Risks in the Age of Generative AI, With Girish Nadkarni, MD, MPH

Nada Elbuluk, MD, MSc, is a dermatologist in California. 

Susan Taylor, MD, a professor and vice chair for Diversity, Equity, and Inclusion at the Perelman School of Medicine. 

What Systemic Changes in Skin Health Equity in Dermatology Are Taking Place?

What Systemic Changes in Skin Health Equity Are Taking Place?

 podcast, Mona Shahriari, MD, assistant clinical professor of dermatology at the Yale School of Medicine and host of 

, led a forward-looking discussion with Susan Taylor, MD, the Bernett Johnson Endowed Professor of Dermatology at the University of Pennsylvania Perelman School of Medicine, and Nada Elbuluk, MD, MSc, board-certified dermatologist and Professor at the USC Keck School of Medicine, Department of Dermatology, focused on the intersection of skin health equity, advocacy, and innovation.

Shahriari emphasized equity does not end at diagnosis. Rather, it extends into public policy, systemic reform, and the broader structures determining access and outcomes. She asked how professional organizations, particularly those centered on skin of color, can translate awareness into durable change. Nearly every major dermatologic society now has a dedicated advocacy arm, a reflection of the growing recognition of policy decisions as directly shaping patient care and physician practice.

Elbuluk highlighted the advocacy committee within the 

, noting its focus on issues disproportionately affecting patients of color. However, she described progress as requiring collaboration and “strength in numbers,” encouraging partnerships across organizations to amplify impact. Taylor offered a concrete example of advocacy in action: policy surrounding pseudofolliculitis barbae (PFB) in the military. Under a directive affecting service members with refractory PFB, individuals who do not improve after a year of treatment may face discharge. In response, the American Academy of Dermatology, in collaboration with multiple dermatologic societies, convened experts to develop a Delphi consensus on optimal PFB management.

Shahriari noted such efforts advance equity broadly. While PFB disproportionately affects men with skin of color, it is not exclusive to any one demographic group. Advocacy addressing disease biology rather than stigma reinforces fairness across patient populations. The discussion then pivoted to innovation, particularly artificial intelligence in dermatology. Shahriari posed a critical question: as new technologies emerge, how can the specialty ensure they narrow rather than widen disparities?

Elbuluk stressed the importance of maintaining a critical lens. Dermatologists should interrogate the datasets informing AI algorithms and diagnostic tools, asking whether they adequately represent diverse skin tones. Blind adoption risks embedding and perpetuating bias at scale. She encouraged clinicians to ask difficult questions of companies developing these tools and to advocate for transparency in data sourcing and validation.

Taylor described representation in decision-making spaces as equally crucial. Being present “in the rooms” where investment, research priorities, and technological development are determined is key to shaping equitable innovation. Without diverse voices at the table, bias can become structurally embedded.

Shahriari illustrated the stakes with a practical example: online image searches for psoriasis often underrepresent skin of color. If search algorithms are trained on non-diverse imagery, patients may fail to recognize their own disease, delaying care. For clinicians, this underscores the downstream consequences of algorithmic bias.

In closing, the panelists offered pragmatic, grassroots actions for 2026. Elbuluk encouraged dermatologists to identify one disease state outside their comfort zone—particularly conditions affecting underrepresented populations—and proactively seek updated literature or educational sessions. She also urged clinicians to join committees within professional societies, noting meaningful change does not require senior leadership titles; consistent engagement at any level matters.

Taylor emphasized collegiality. Dermatology is a community, she said, and clinicians should feel empowered to consult peers when uncertain about a diagnosis in any patient population. Shahriari echoed this sentiment, advocating for small, consistent shifts, such as diversifying personal teaching image libraries, collectively driving meaningful change. For practicing dermatologists, the message was clear: advocacy, critical evaluation of innovation, and everyday clinical intentionality are central to advancing skin health equity.

Editor’s note: This summary was developed with the help of AI tools.

In this segment of the recent Skin of Color Savvy podcast, the value of advocacy and meaningful change in skin health equity is highlighted.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

 began picking up steam in February, with several key approvals from the US Food and Drug Administration (FDA) and multiple key trial results being announced. The momentum from last month promises more news to come as we begin to round out the first quarter of 2026.

As we enter March, which looks to be a busy month for endocrinology, the

 editorial team has collected 6 of the most impactful headlines of February 2026 – catch up on any news you may have missed below.


FDA Approves 3 New Pediatric Indications for Once-Weekly Somapacitan-beco (Sogroya)

On February 27, the FDA approved 3 new indications for once-weekly somapacitan-beco (Sogroya) 5 mg, 10 mg, and 15 mg injections for pediatric patients with Idiopathic Short Stature (ISS), short stature born Small for Gestational Age, and growth hormone deficiency. This indication opened the drug’s accessibility to children ≥2.5 years of age, taking the form of a once-weekly treatment.


FDA Approves ET-600 Desmopressin Acetate (Desmoda) for Central Diabetes Insipidus

On February 25, 2026, the FDA approved ET-600 under the name Desmoda for the treatment of central diabetes insipidus in pediatric patients. ET-600 is now the first and only FDA-approved oral liquid formulation of desmopressin following this decision. The approval was based in large part on results from a bioequivalence study completed in March of 2025.


ACHIEVE-3: Orforglipron Achieves Superiority to Oral Semaglutide in Poorly Controlled T2D

On February 26, 2026, Eli Lilly announced detailed results from the ACHIEVE-3 trial, highlighting the results of orforglipron’s head-to-head comparison with semaglutide in patients with 

. Orforglipron demonstrated improvements in A1c, weight loss, non-HDL and HDL cholesterol, total cholesterol, blood pressure, and triglycerides. Additionally, this dose of orforglipron is not required to be taken with food or water.


VESPER-3: Positive Results of Long-Term GLP-1 PF’3944 in Overweight and Obesity Without T2D

Parent company Pfizer announced the results of their VESPER-3 phase 2b trial on February 3, 2026, which highlighted their investigative long-term GLP-1 PF’3944’s superiority to placebo in weight reduction in . The trial’s 2 primary endpoints – demonstrating efficacy in achieving continued weight loss after switching from weekly to monthly dosing and demonstrating PF’3944’s capacity to switch to a 4-fold equivalent monthly dose safely – were both met. Full data from VESPER-3 will be presented at the American Diabetes Association Scientific Sessions on June 6, 2026.


Diabetes Dialogue: Launch of the Zepbound KwikPen

In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the groundbreaking release of Eli Lilly’s Zepbound KwikPen. This multi-dose device, available now through LillyDirect, consolidates the traditional 4 single-use pens per month into 1 pen with 4 injections included. This allows for safer dose adjustment than prior vial formulations, as the latter did not include preservatives and were not intended for repeat punctures.


Diabetes Dialogue: Implantable Insulin Pumps and Interoperability

In this episode, Isaacs and Bellini discuss the new implantable insulin pump from Portal Diabetes, which has been granted Breakthrough Device designation from the FDA. The device delivers insulin intraperitoneally, which allows for rapid absorption into the portal circulation. This mechanism allows for the elimination of pre-meal bolusing and may potentially improve exercise safety due to shorter insulin tail effects.

Articles

February 2026 delivered notable endocrinology advances across FDA approvals, metabolic trial readouts, and diabetes technology. Once-weekly somapacitan-beco gained three new pediatric growth indications, expanding use to children aged ≥2.5 years. ET-600 (Desmoda) became the first FDA-approved oral liquid desmopressin for pediatric central diabetes insipidus. In T2D, Lilly’s oral GLP-1 orforglipron outperformed oral semaglutide across glycemic, weight, lipid, and BP endpoints with fewer administration constraints. Pfizer’s PF’3944 supported durable weight loss with monthly dosing transitions.

Catch up with FDA decisions, key trial results, podcast updates, and more.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

6 Endocrinology Headlines You Missed in February 2026

Iben Lyskjær, PhD, is an associate professor and leader of the Lyskjær Group at the Department of Molecular Medicine (MOMA) at Aarhus University.

Ablation, a minimally invasive procedure, may be as effective as surgery for treating small kidney cancers, with faster recovery and fewer complications, according to new research.

The findings come from a 10-year nationwide registry-based cohort study of Danish adults following 1900 patients diagnosed with stage T1a renal cell carcinoma and suggest ablation could potentially reduce complications, hospital stays, and costs.

The study included 1,862 patients, with a median age of 64, and a majority of men (n = 1305). They were categorized into the ablation group (n = 540), the resection group (n = 1002), or the nephrectomy, surgical removal of all or part of a kidney, group (n = 320). In the ablation group, 42 patients underwent radiofrequency ablation, while the remaining patients underwent cryoablation.

There was no evidence of a difference in the risk of cancer progression between patients who had ablation and the resection group. However, local recurrence of the disease was more frequent following ablation (2.41%) than resection (1.20%) and nephrectomy (0%).

According to investigators, distant metastasis occurred more frequently in patients who underwent nephrectomy (4.38%) than in those who underwent resection (1.90%) and ablation (1.67%). Investigators noted patients with ablation had the shortest hospital stays, and most returned home the same day. Additionally, the report of the fewest 30-day post-treatment hospital contacts, suggested a reduced instance of complications.

For additional insight into the new research, 

spoke to Iben Lyskjær, PhD, associate professor and leader of the Lyskjær Group at the Department of Molecular Medicine (MOMA) at Aarhus University.

 The data was prefaced by the fact that stage T1a renal cell carcinoma is often found incidentally during CT scans for other reasons. How has this led to a gap in care, and how can clinicians proactively manage this pressure on their health care systems?

Lyskjær: The widespread use of cross-sectional imaging has led to a marked increase in the incidence of small renal masses detected incidentally, particularly stage T1a tumors. Many of these lesions are asymptomatic and biologically indolent, but once detected, they enter a clinical pathway that often includes repeated imaging, multidisciplinary evaluation, and intervention.

This has created a structural pressure on healthcare systems: more patients are diagnosed, but not all necessarily require invasive treatment. The key challenge is distinguishing which tumors require active intervention from those that can be safely monitored.

Proactive management involves strengthening risk stratification strategies, incorporating active surveillance where appropriate, and ensuring access to minimally invasive treatment options such as ablation for selected patients. The goal is not simply to treat more, but to treat more appropriately.

HCPLive: When discussing the prospect of ablation with their patients compared to standard of care, what key factors and risk identifiers should clinicians consider?

Lyskjær: When discussing ablation compared to partial nephrectomy, clinicians should consider:

Tumor size (strictly ≤4 cm for T1a in most settings)

Patient preference after balanced counseling

Yet, shared decision-making remains central.

Local recurrence of the disease was more frequent following ablation than resection and nephrectomy. Can you explain this finding in the context of why ablation remains a beneficial option? Is there ever a point when it wouldn’t be?

It is true that local recurrence rates are generally higher after ablation compared to surgical resection. This is expected because surgery physically removes the entire tumor with a margin, whereas ablation relies on complete thermal destruction in situ.

However, several important nuances should be emphasized:

Local recurrences after ablation are often detected early through structured follow-up.

Cancer-specific survival for appropriately selected T1a tumors appears comparable in many studies.

Therefore, the slightly higher local recurrence rate must be interpreted in the context of lower procedural burden and shorter hospital stay. Ablation are not be appropriate for larger tumors, centrally located lesions, or in cases where imaging guidance cannot ensure adequate margins.

Are there any findings on whether radiofrequency ablation had any distinct outcomes from cryoablation? Is this an area of research you would consider meaningful?

Lyskjær: Our study primarily focused on cryoablation, with only few radiofrequency ablation procedures performed, and therefore we could not compare the difference in outcome of these. While radiofrequency ablation and cryoablation are both established thermal techniques, cryoablation offers certain technical advantages, including real-time visualization of the ice ball, which may allow more precise control of margins.

Further direct comparative research would be meaningful, particularly in standardized cohorts with long-term follow-up. However, operator experience and institutional expertise are likely just as important as the specific energy modality.

HCPLive: Looking ahead, how should clinicians implement these findings into their healthcare systems immediately to build a long-term strategy to improve patient outcomes?

Lyskjær: Clinicians should not interpret our findings as a call to replace surgery, but rather to refine patient selection.

Ensuring that ablation is considered in multidisciplinary tumor boards for appropriate T1a cases

Strengthening follow-up protocols after ablation

Integrating patient-specific factors (comorbidity, renal function, life expectancy) into decision-making as well as patient preference

Continued evaluation of functional outcomes

Clear national or international guidelines on patient selection

The overarching aim is individualized care — selecting the right treatment for the right patient — rather than promoting one modality universally.

Minimally invasive procedure effectively treats small kidney cancers. EurekAlert! Published March 3, 2026. Accessed March 3, 2026. 

https://www.eurekalert.org/news-releases/1117633

A 10-year Danish registry cohort of 1,862 adults with T1a RCC found ablation yielded cancer progression risk comparable to partial resection, while shortening length of stay and reducing early post-treatment hospital contacts. Local recurrence was modestly higher with ablation (2.41%) versus resection (1.20%) and nephrectomy (0%), yet recurrences are often detected early and amenable to repeat ablation. Distant metastases were most frequent after nephrectomy. Rising incidental detection of small renal masses intensifies demand for risk stratification, surveillance, and appropriate minimally invasive options.

Lyskjaer walks clinicians through 10-year data from a nationwide cohort study comparing ablation and surgery for renal cancer.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Ablation Offers Faster Recovery, Fewer Complications for Small Kidney Cancers

This segment of the February episode of The Medical Sisterhood podcast highlights burdens faced by those balancing motherhood with being a physician.

What Are the Invisible Burdens Carried By Physician Moms?

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Catch up on durability data and real-world insight from trials across inflammatory bowel disease and short bowel syndrome.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

5 Gastroenterology Headlines You Missed in February 2026

Akin discussed how avapritinib continues to demonstrate its benefit in indolent systematic mastocytosis.

Long-Term PIONEER Data Reinforce Avapritinib’s Benefit–Risk Profile in ISM, with Cem Akin, MD

Sayna Norouzi, MD, is an assistant professor of medicine and clinical nephrologist at Loma Linda University Medical Center

Norouzi discusses a recent review where 11 clinicians described C3G pathology and diagnosis.  

C3 Glomerulopathy

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.

Deep Diving into the Pathogenesis of C3 Glomerulopathy, With Sayna Norouzi

At AAAAI 2026, Han reports pooled ANCHOR data showing depemokimab improved nasal symptoms, QoL, and cut rescue interventions.

Twice-Yearly Depemokimab Reduces Rescue Use in Recurrent CRSwNP, With Josesph Han, MD

Catch up on new trial readouts, trends in hepatitis B birth dose vaccination, updates in a rare hepatic disease in honor of Rare Disease Day, and more.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Alpha-1 antitrypsin deficiency

6 Hepatology Headlines You Missed in February 2026

In this segment from the latest episode of the Skin of Color Savvy podcast, progress in skin health equity and advancements still needed in 2026 are highlighted.

Where Are We in 2026 in Skin Health Equity Progress?

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Podcasts

Isaacs and Bellini discuss recent updates on Eli Lilly's orforglipron and retatrutide and Novo Nordisk's UBT251, along with other recent GLP-1 news.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Diabetes Dialogue: Orforglipron, Retatrutide, and Other GLP-1 Updates

Experts introduce the contemporary treatment paradigm for oHCM, emphasizing earlier diagnosis, cardiac myosin inhibitor use, and objective assessment of “asymptomatic” patients.

Video Series

Modern oHCM Management: Earlier Diagnosis and Cardiac Myosin Inhibitors

Wei-Xing Zong, PhD, is Distinguished Professor and Chair of the Department of Chemical Biology at Rutgers University.

New research links dietary protein, ammonia buildup, and liver cancer growth, raising questions about targeted nutrition in HCC risk management. 

Latest News

SUMMIT: Bezuclastinib Delivers Durable, Deepening Symptom Relief in NonAdvSM, With Cem Akin, MD

Mapping Medical Misinformation Risks in the Age of Generative AI, With Girish Nadkarni, MD, MPH

What Systemic Changes in Skin Health Equity Are Taking Place?

6 Endocrinology Headlines You Missed in February 2026

Ablation Offers Faster Recovery, Fewer Complications for Small Kidney Cancers